Compare NTLA & FUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | FUN |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2016 | 2023 |
| Metric | NTLA | FUN |
|---|---|---|
| Price | $17.38 | $21.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 12 |
| Target Price | $20.02 | ★ $23.75 |
| AVG Volume (30 Days) | ★ 6.7M | 2.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $67,671,000.00 | ★ $3,100,289,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | $62.75 | $3.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | 14.45 |
| 52 Week Low | $7.95 | $12.51 |
| 52 Week High | $28.24 | $33.50 |
| Indicator | NTLA | FUN |
|---|---|---|
| Relative Strength Index (RSI) | 69.19 | 46.39 |
| Support Level | $11.73 | $20.26 |
| Resistance Level | $27.61 | $21.22 |
| Average True Range (ATR) | 1.21 | 1.46 |
| MACD | 0.28 | -0.44 |
| Stochastic Oscillator | 84.38 | 18.56 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS. The parks are family-oriented, with recreational facilities for people of all ages, and provide clean and attractive environments with exciting rides and immersive entertainment. The Company generates revenue from sales of admission to the amusement parks and water parks, from purchases of food, merchandise and games both inside and outside the parks, from the sale of accommodations and other extra-charge.